Drug delivery system (DDS) is closely related with physicochemical properties of drug, mechanism of delivery, and indication.
Our company improve clinical outcome through PCI-MetricTM Technology that is the most efficient strategy of drug delivery.
Drug delivery system (DDS) is closely related with physicochemical properties of drug, mechanism of delivery, and indication. Our company improve clinical outcome through PCI-MetricTM Technology that is the most efficient strategy of drug delivery.
· Local delivery
· Systemic delivery
· Solubility, pKa, LogP,,, etc
· Protein binding
· Membrane desposition
· RBC desposition, etc
· Liposome
· LNP
· Micelle
· Albumin particle
When a drug is administered subcutaneously, it is rapidly absorbed into the blood capillaries, that leads higher peak concentration, bioavailability close to 100%, and immediate drug action. Therefore, it is used in cases where a prompt therapeutic effect is required such as antibiotics, and pain. Additionally, with repeated administration, it exhibits large fluctuations in plasma concentration similar to intravenous administration. However, in the case of GLP-1 receptor agonists (GLP-1RAs), the purpose is long-term repeated administration. Particularly, with subcutaneous injection, the rapid initial rise in plasma concentration can lead to gastrointestinal side effects such as nausea and vomiting. Due to these limitations, there is a need for novel drug delivery systems for the treatment of chronic diseases such as diabetes and obesity.
S-Nzyme technology is a platform technology designed to delay the initial absorption of peptide drugs, including GLP-1 receptor agonists (GLP-1RAs), thereby minimizing fluctuations in blood drug concentrations. This is achieved by forming nanoparticles through the conjugation of peptide drugs with biocompatible polymers, which significantly increases the apparent molecular size—by tens to hundreds of times—resulting in slower transport across capillaries and delayed absorption. Through this mechanism, the fluctuations in blood concentration upon repeated administration are minimized, ultimately reducing side effects such as nausea and vomiting. This technology is particularly well-suited for chronic diseases requiring long-term administration, such as diabetes. In addition, it allows for increased dosage administration, which can further enhance therapeutic flexibility and efficacy.
